Aaron Osborne, MD, chief medical officer and chief development officer at Nanoscope Therapeutics, talks about vision restoration in clinical trials of the company's optogenetic therapy for people with advanced vision loss from retinitis pigmentosa and Stargardt disease.

Known as The Lighthouse Study, the Phase 1/2 trial is expected to begin in mid-2023

During his Proctor Award Lecture, Dr. Pierce reviewed encouraging clinical trial results for Editas’ CRISPR/Cas9 treatment for people with LCA10

News | Budd Tucker Honored with Award for Advancements in Retinal Therapy Development by Foundation Fighting Blindness

April 28, 2023. Henry Klassen, MD, PhD, co-founder of jCyte and clinical researcher at UC Irvine, talks to host Ben Shaberman about jCyte's clinical trial results and future plans for developing its cell-based therapy for preserving vision caused by retinitis pigmentosa, Usher syndrome, and related retinal conditions.